Tollip Is a Mediator of Protein Sumoylation

Alessia Ciarrocchi1,°a, Romina D’Angelo1,°, Chiara Cordiglieri1,°b, Ada Rispoli1, Spartaco Santi2, Massimo Riccio2,°c, Simona Carone1, Anna Laura Mancia1,°d, Simone Paci1, Elena Cipollini1, Davide Ambrosetti1, Marialuisa Melli1,°

1 Department of Biology, Bologna University, Bologna, Italy, 2 Institute of Organ Transplantation and Immunocitology-ITOI, C.N.R, Bologna, Italy

Abstract

Tollip is an interactor of the interleukin-1 receptor involved in its activation. The endosomal turnover of ubiquitylated IL-1RI is also controlled by Tollip. Furthermore, together with Tom1, Tollip has a general role in endosomal protein traffic. This work shows that Tollip is involved in the sumoylation process. Using the yeast two-hybrid technique, we have isolated new Tollip partners including two sumoylation enzymes, SUMO-1 and the transcriptional repressor Daxx. The interactions were confirmed by GST-pull down experiments and immunoprecipitation of the co-expressed recombinants. More specifically, we show that the TIR domain of the cytoplasmic region of IL-1RI is a sumoylation target of Tollip. The sumoylated and unsumoylated RanGAP-1 protein also interacts with Tollip, suggesting a possible role in RanGAP-1 modification and nuclear-cytoplasmic protein translocation. In fact, Tollip is found in the nuclear bodies of SAOS-2/IL-1RI cells where it colocalizes with SUMO-1 and the Daxx repressor. We conclude that Tollip is involved in the control of both nuclear and cytoplasmic protein traffic, through two different and often contrasting processes: ubiquitylation and sumoylation.

Introduction

Tollip is an interactor of the Toll family of proteins, which are highly conserved in evolution from Drosophila to Man, and include the Toll-like and interleukin-1 (IL-1) receptors, all involved in the inflammatory response. The sequence of Tollip, spanning 274 amino acids, contains some characterized functional domains. A C2-like domain, lacking the two conserved Asp residues critical for Ca2+ binding and present in numerous eukaryotic proteins as a Ca2+-binding site and in numerous eukaryotic proteins as a binding site for a variety of phospholipids [1]. A C-terminus ubiquitin binding CUE domain identified by Shih et al. [2] as a ubiquitin binding site that mediates intramolecular monoubiquitylation. At the amino-terminal (aa 1–54), a GAT/TOM1 interacting domain is also described [3]. So far, Tollip has been involved in two main functions. The first, proposed by Burns and collaborators [1], indicates Tollip as an interactor of the IL-1 receptor TIR domain, mediating the binding of the serine/threonine kinase IRAK-1 to the activated receptor complex, thus being integral part of the IL-1RI signaling cascade. Later, Yamakami & Yokosawa [4] proposed a negative regulatory role of Tollip on the IL-1β and TNF-α signaling pathways, in agreement with the inhibition of NF-κB activation observed following Tollip overexpression [1,5]. The second function, described by Yamakami et al. [3], concerns the interaction of Tollip with Tom1, Ubiquitin and Clathrin in a high molecular mass complex involved in protein sorting. In agreement with this proposal, an endosomal function of the protein was suggested by Katoh et al., [6,7]. In addition, Brisoni et al. [8] have recently shown that Tollip is required in the sorting of the IL-1RI at late endosomes, further clarifying its involvement in the IL-1 inflammatory pathway. Zhang and Ghosh [5] have shown that Tollip associates not only with IL-1RI but also with the TLR2 and TLR4 receptors when activated by LPS stimulation. Also this interaction results in the suppression of TLR-mediated cellular responses through the inhibition of phosphorylation and kinase activity of IRAK1.

We show, for the first time, the involvement of Tollip in the sumoylation process. Sumoylation is a post-translational modification of proteins that conjugate SUMO-1 with a lysine of the target peptide through the formation of a covalent bond. This reaction is very similar to the ubiquitylation process and it is catalyzed by three enzymes, that act in succession: 1) El, the dimeric activation complex, composed of the proteins Aosl and Uba2; 2) the single E2 conjugation enzyme named Ubc9; 3) at least three types of E3 ligases. The first group of E3 ligases is encoded by the protein inhibitor of activated signal transducer and activator of transcription (PIAS) family and entails the 5 mammalian members: PIAS1, PIAS3, PIASxα/ARIP3, PIASxβ, and PIASγ. These ligases are characterized by the presence of a RING-finger-like structure essential to their function. The second...
group is represented by the RanBP2/Nup358 protein, which is a component of the nucleopore complex and does not contain the ring finger domain [9]. The third type is Pc2, a member of the polycomb group of proteins (PcG) involved in gene silencing. Pc2 recruits the CctBP repressor to the PcG nuclear bodies and enhances its sumoylation [10]. These ligases are not protein specific and show overlapping targets. In fact, it is not clear how the specificity of the sumoylation reaction is achieved. It seems likely that more ligases or cofactors exist and contribute to the specificity of the modification process.

In order to further characterize the function of Tollip, we have screened a cDNA library by the yeast two-hybrid system, looking for Tollip partners. In addition to the known interactors, TOM1, Tollip itself and ubiquitin, we have isolated Daxx, SUMO-1, and the E2 (Ubc9) and E3 (ARIP3) sumoylation enzymes. This work shows that Tollip binds Ubc9, SUMO-1 and at least three ligases of the Pias family and is itself sumoylated. The binding domain of Tollip to the ligases of the PIAS family and of the ARIP3 ligase to Tollip are identified. In particular, in a SAOS-2 clone enriched in IL-1RI receptors (SAOS-2/IL1RI), Tollip translocates into the nucleus where it co-localizes with SUMO-1 and Daxx, in nuclear bodies. The SAOS-2/IL1RI clone was derived from the SAOS-2 osteosblasta cell line which constitutively expresses IL-1RI [11,12] and was kindly provided by Dr Sandra Marmiroli (Modena and Reggio Emilia University). Our results may correlate with the interaction of Tollip with the RanGAP-1 protein. Furthermore, we identify the cytoplasmic domain of IL-1RI as a target of Tollip sumoylation. We propose that Tollip is involved in the nuclear translocation of proteins either as a sumoylation cofactor or a ligase.

**Results**

**Tollip interacting proteins**

The yeast two-hybrid mating assay was carried out as described in material and methods. High stringency screening of a cDNA library from rat brain hemispheres, allowed the isolation of 310 positive recombinant clones that were analyzed by PCR amplification. 213 cDNA recombinants showed a single band of amplification that was further characterized. Table 1 lists some of the isolated cDNAs (column 1) with the corresponding aminoacid regions (column 2) and the number of independent colonies for each isolated recombinant clone (column 3). The majority of cDNA recombinants were coding for ubiquitin or ubiquitin fused to ribosomal RNA subunits. This is in agreement with the presence of a ubiquitin binding CUE domain at the C-terminus of Tollip and with the described cytoplasmic role of ubiquitinated Tollip [3,2,3]. The already described binding of Tollip to TOM1 and its homodimerization are consistent with the published results [3,5]. Interestingly, proteins involved in the sumoylation process (SUMO-1, Ubc9, ARIP3) and the transcriptional repressor Daxx are among the interactors that we have isolated. The interactions of Tollip with some of the identified proteins were confirmed by GST-pull down experiments. The B42 fused 35S-peptides were incubated with GST-Tollip or GST beads and the interaction was analyzed by SDS-PAGE and autoradiography (Fig. 1A). All the peptides analyzed interact with Tollip but not with the GST control. B42 alone does not interact with Tollip, showing the specificity of the reaction. The cytoplasmic region of the IL-1RI accessory protein (IL-1RcP) and IL-1RI were used as positive control. To confirm the interactions observed in yeast, 293T cells were transfected with the pRK7-HA-Tollip cDNA together with constructs coding for Ubc9 (Fig. 1B) or the Flag-ARIP3 fusion proteins (Fig. 1D). 293T cells expressing the unrelated protein HA-Cystatin B, together with Ubc9 (Fig. 1C) and Flag-ARIP3 (Fig. 1E) were used as control. The immunoprecipitation with anti-HA antibodies (abs) shows that Ubc9 (B) and Flag-ARIP3 (D) co-immunoprecipitate with HA-Tollip but not with the control protein (C and E), confirming the specificity of the binding.

**Table 1.**

| cDNA | Isolated protein fragment | N of independent colonies |
|------|--------------------------|---------------------------|
| Ubiquitin conjugating enzyme 9 (Ubc9) | 1–159 aa (full length) | 45 |
| Death domain interacting protein (Daxx) | 643–739 | 5 |
| Target of Myb-1 homologue (TOM1) | 3–492 | 5 |
| Androgen receptor interacting protein 3 (ARIP3) | 64–572 | 3 |
| Small ubiquitin-like modifier 1 (SUMO-1) | 448–572 | 2 |
| Tollip | 1–101 aa (full length) | 1 |
| Leucin Rich Protein | 141–274 | 1 |
| Brain expressed X-linked 2 (Bex1) | 671–832 | 1 |
| Receptor for Activated C Kinase (RACK 1) | 33–129 | 1 |
| ING 1 tumor suppressor | 241–317 | 1 |
| Ubiquitin family | 248–276 | 1 |
| Ubiquitin | 1–76 (full length) | 71 |
| Ubiquitin/A52 fusion protein | 72–105 | 7 |
| Ubiquitin/S27 fusion protein | 2–157 | 4 |

doi:10.1371/journal.pone.0004404.t001

**Tollip interaction with the PIAS family of proteins**

The site of interaction of HA-Tollip with ARIP3 is analyzed in Fig. 2. The carboxyl- and amino-terminus deletion mutants schematized in panel A were used to identify the Tollip domain(s) interacting with ARIP3. Protein extracts from 293T cells transfected with wild type or mutant HA-Tollip and Flag-ARIP3 were immunoprecipitated with anti-HA abs and analyzed by western blot. Panel B shows the SDS-PAGE of the immunopre-
cipitated samples (lanes 2) next to the respective protein extracts (lanes 1) stained with anti-Flag abs. All Tollip mutants interact with ARIP3 with the exception of D6, where the entire N-terminus and C2 domain is removed. On the other hand, the D7 construct spanning aa 54–179 (C2 domain) and D5 spanning aa 134–274 (C-terminus of the C2 plus the CUE regions), bind ARIP3. Thus, the 134–179 peptide of the C2 region is sufficient for the interaction and contains the ARIP3 binding site. The staining with anti-HA abs (panel C) shows that all mutants are efficiently expressed (lanes 1) and immunoprecipitated (lanes 2).

We have also analyzed the Tollip interacting sites of ARIP3 (Panels D and E). ARIP3 entails 572 amino acid with three functionally characterized domains [13,14]: 1) The SAP (SAF-A/B, Acinus PIAS) domain from aa 11–45 that may be a DNA binding site; 2) The RING domain from aa 347–388, responsible for the ligase function; 3) The androgen receptor binding site spanning aa 443–548. We have generated the three carboxyl-terminus deletion mutants shown in panel D. The wild type and mutant pCDNA3.1-Flag-ARIP3 constructs were co-transfected with pRK7-HA-Tollip cDNA. The cell extracts were immunoprecipitated with anti-HA abs and analyzed by western blot as shown in panel E. Lane 1 shows the protein extract and lane 2 the immunoprecipitated samples. The Flag-ARIP3-Aa and Ab mutants, deleted of the androgen receptor and ring domain respectively, co-immunoprecipitate with HA-Tollip while the Δc mutant, containing aa 1–169, is not detectable on the gel. This shows that HA-Tollip interacts with a region of ARIP3 spanning residues 169–347. This domain is highly conserved in the PIAS family of proteins. Thus, we investigated the possible interaction of Tollip with other members of the family. As expected, HA-Tollip interacts with both PIAS1 and PIASxβ (Fig. 2F and G). Immunoprecipitation of Flag-PIAS1 and Flag-PIASxβ with HA-Tollip deletion mutants Δ5 and Δ6 shows that the carboxyl-terminus region of the C2 domain represents the interaction site with the E3 ligases of the PIAS family that we have examined.

**Tollip triggers protein sumoylation and is itself sumoylated**

The interaction of Tollip with the sumoylation enzymes suggests that Tollip is sumoylated and perhaps has a role in the sumoylation process itself. The analysis of the rat amino acid sequence (accession BC133067.1) indicates at least 3 putative sumoylation sites within the C2 domain (the lysines at position 96, 143, and 162). However, the transfection of 293T cells with HA-Tollip together with Flag-SUMO-1, Ubc9, and Flag-ARIP3 shows that, under the conditions tested, Tollip migrates as a monomer at the expected molecular weight of 29 kDa (Fig. 3A). No additional slow migrating bands can be detected. This set of experiments suggests that Tollip is not covalently modified. However, the presence of ubiquitin-like protease activity (Ulp) in native cell lysates combined with the short half-life of the SUMO-1 modification [15,16] may destabilize the process. Thus, we have carried out an additional experiment were 293T cells were co-transfected with HA-Tollip and SUMO-1 and the cells were lysed under denaturing conditions, to block protease activity and exclude non covalent association with interacting proteins.
control cells were transfected with SUMO-1 only. The staining of the protein extracts with anti-SUMO-1 abs generates a similar pattern of bands in the two samples (Fig. 3B, lanes 1 and 2). The immunoprecipitation of the same protein extracts with anti-HA abs is shown in panel B lanes 3–6. Both SUMO-1 and anti-HA abs generate bands migrating in corresponding positions of the gel, at a molecular weight higher than monomeric Tollip (compare lanes 3 and 5). This result confirms that Tollip is sumoylated, possibly in more than one lysine residue. It should be noticed, however, that Tollip may be dimeric as well as ubiquitinated [2,3] and this makes it difficult to relate the molecular weight to the number of SUMO-1 molecules covalently bound to it. We can conclude that in 293T cells Tollip is transiently sumoylated. The low intensity of the sumoylation bands detected in the immunoprecipitation blot

Figure 2. Tollip and ARIP3 interacting domains. A) Schematic representation of HA-Tollip deletion mutants. The black box represents the C2 domain (aa 54–179), the grey box represents the CUE domain (aa 229–274). HA-Tollip wt: aa 1–274; Δ1: aa 1–229; Δ2: aa 1–179; Δ3: aa 54–274; Δ4: aa 94–274; Δ5: aa 134–274; Δ6: aa 179–274; Δ7: aa 54–179. In all western blots described in this figure, lane 1 contains the protein extract and lane 2 the immunoprecipitated proteins. B) Western blot of protein extracts from 293T cells, transfected with Flag-ARIP3 cDNA and with the indicated HA-Tollip deletion mutants, before (lane 1) and after (lane 2) immunoprecipitation with anti-HA abs. The staining is with anti-Flag abs. C) Western blot from the same protein extracts as in B stained with anti-HA abs. D) Schematic representation of the Flag-ARIP3 deletion mutants. The circle represents the SAP domain (aa 11–45), the white box with black stripes represents the RING domain (aa 347–388) and the black box with white stripes represents the ARID domain (aa 443–548). Flag-ARIP3 wt: aa 1–572; Δa: aa 1–467; Δb: aa 1–347; Δc: aa 1–169. E) Western blot of protein extracts from 293T cells transfected with HA-Tollip and the indicated Flag-ARIP3 deletion mutants. The protein extract was immunoprecipitated with anti-HA abs and stained with anti-Flag antibodies. F) Western blot of protein extracts from 293T cells transfected with the Flag-PIAS-1 cDNA together with HA-Tollip wt and mutants as indicated. Immunoprecipitation with anti-HA abs; staining with anti-Flag abs. G) Western blot of protein extracts from 293T cells transfected with the Flag-PIASx cDNA together with the HA-Tollip wt and mutants as indicated. The protein extract was immunoprecipitated with anti-HA abs and stained with anti-Flag abs. H, I) Western blots of the same samples as in F and G respectively, stained with anti–HA abs.
may be due to the process of de-sumoylation of modified Tollip that certainly occurs. To test the possible effect of Tollip on the sumoylation process, 293T cells were transfected as indicated and the protein extracts were analyzed by western blot with anti-Flag abs (Fig. 3C). The sumoylation bands are not detectable in the protein extracts of not transfected cells (lane 1). The transfection with SUMO-1 cDNA shows a band ladder in the high molecular weight range suggesting sumoylation of numerous proteins (lane 2). Cotransfection of SUMO-1 and Tollip increases the intensity of the sumoylated bands, suggesting activation of the sumoylation process (lanes 3 and 5). This trigger is specifically due to Tollip, since overexpression of an unrelated cDNA does not activate the sumoylation process (lane 4). The intensity of the actin bands shows that the amount of proteins loaded on each lane is the same.

The IL-1 receptor is a Tollip sumoylation target

The effect of Tollip on sumoylation has prompted the search for sumoylation targets. Burns et al. [1] and Brissini et al. [8] have described the interaction of Tollip with the IL-1 receptors and its involvement with the receptor intracellular traffic. We have analyzed the possible modifications of the receptor co-transfected with the Tollip and the SUMO-1 proteins. The transfection of the full length IL-1RI receptor in 293T cells gave poor efficiency and very low expression of the protein. As the cytoplasmic region of the receptor interacts with Tollip (Fig. 1A), we have used this domain for the transfection experiments. 293T cells were transfected as indicated in Fig. 4A and the protein extracts were stained with anti IL-1RI abs. Transfection of the cytoplasmic region of the IL-1RI shows a single band migrating at about 25 KDa. Cotransfection of the cells with plasmids expressing SUMO-1 (lane 2) and the sumoylation enzymes (lane 3) only slightly modifies the banding pattern of the receptor protein. In addition to the expected band of the cytoplasmic receptor, a second band migrating at the approximate molecular weight of 40 kDa can be detected. However, the transfection of the cells with HA-Tollip together with SUMO-1 triggers the formation of a banding pattern ranging between 25 and 100 kDa molecular weight (lane 4). The western blot of the cell extract immunoprecipitated with anti-HA abs and stained with anti-SUMO-1 abs shows that the band ladder contains SUMO-1 (Fig. 4B lane 2). After immunoprecipitation, at least four of the sumoylated bands stained by the abs are co-migrating with the receptor bands (compare lanes 1 and 2). This strongly suggests that sumoylation modifies the migration characteristics of the cytoplasmic domain of the receptor. We can conclude that the interaction of Tollip with the sumoylation enzymes triggers the sumoylation of IL-1RI. Figures 4D and E analyze the banding pattern of the cytoplasmic receptor in cells transfected with the Δ1 and Δ2 receptor deletion mutants indicated in C. Interestingly, the cytoplasmic mutant 555–503 (Δ2) is not sumoylated (Fig. 4E) while the fragment spanning aminoacids 555–531 (Δ1) is sumoylated (Fig. 4D). The sumoylated residues are one or more lysines present in the IL-1RI sequence 504–530 at the possible following positions: 504, 507, 509 and 527. These lysines are part of the phylogenetically conserved BOX 3 of the TIR homology region of the receptor. It should be noticed

Figure 3. Sumoylation of Tollip. A) Western blot analysis of protein extracts from 293T cells transfected as indicated above the figure and stained for the proteins indicated on the right. B) Western blot analysis of protein extracts from 293T cells transfected with HA-Tollip and SUMO-1 (lane 1) and SUMO-1 only (lane 2) stained with anti-SUMO-1 abs. The same protein extracts were immunoprecipitated with anti-HA abs and stained with anti-SUMO-1 abs (lanes 3 and 4) and, after stripping of the membrane, they were stained with anti-HA abs (lanes 5 and 6). These samples were electrophoresed in 8% SDS-PAGE. C) Western blot of protein extracts from 293T cells transfected and stained as indicated. doi:10.1371/journal.pone.0004404.g003
that the sumoylation of IL-1RI is stable and clearly detectable even in cells lysed in non-denaturing buffer.

A well-known sumoylation target is the GTPase activated protein RanGAP1, involved in the directional movement through the nucleo-pore complex (NPC). RanGAP1 is constitutively modified \textit{in vivo} and remains modified even under conditions where all other SUMO-1 targets are de-sumoylated [17]. Fig. 4F shows a western blot of 293T cells transfected with Flag-SUMO-1 together with HA-Tollip. The protein extract (lane 1) and the proteins immunoprecipitated with anti-HA abs (lane 2) are stained with anti-SUMO-1 abs. G) Western blot analysis of protein extracts from 293T cells transfected with Flag-SUMO-1 together with HA-Tollip (lane 1) or HA-Cystatin B (lane 2) and immunoprecipitated with anti-HA abs. H) Western blot analysis of protein extracts from 293T cells transfected as indicated above the figure, stained with anti-RanGAP-1 abs. Lanes 1 and 3 contain the protein extract and lanes 2 and 4 contain the immunoprecipitated proteins. The asterisks indicate the position of the immunoglobuline band.

doi:10.1371/journal.pone.0004404.g004

The role of sumoylated Tollip

So far, the function of Tollip has been linked to the endosomal degradation machinery, as an adaptor molecule, operating together with Tom1, on the ubiquitination system of protein degradation. Recently, Brissoni et al. [8] have shown that ubiquitinated Tollip is necessary to sort ubiquitinated IL-1RI at late endosomes, acting as a ubiquitin receptor. SUMO-1 is a
ubiquitin-like modifier that regulates several essential cellular processes, i.e. nuclear-cytoplasmic signaling and transport, and regulation of gene expression [18]. However, sumoylation does not usually tag proteins to degradation but seems to enhance their stability, modulate their nuclear compartmentalization, sometimes competing with ubiquitin for lysine modifications, with quite a different outcome on cell function [19]. Perhaps, the most studied role of SUMO-1 modification on proteins is that of nuclear translocation [17,9]. As we have found that Tollip can be sumoylated and interacts with Ran-GAP1, we have analyzed its cellular localization both in cells that do not express the IL-1 receptor (HeLa cells) and in cells that constitutively express IL-1RI (SAOS-2/IL1R cells). Fig. 5 panels A–D show the double fluorescence confocal analysis of HeLa cells co-transfected with SUMO-1 and Tollip. In agreement with the published data, Tollip is visible in small aggregates in the cytoplasm, in the perinuclear region in a position that may correspond to the Golgi apparatus and/or to endosomes [3]. SUMO-1 is partly diffused in the nuclear region, and partly aggregated in what may be PML bodies. None of the cells that we have examined shows colocalization between SUMO-1 and Tollip (panels C and D). In contrast, a different cellular distribution of the two proteins is observed in the human SAOS-2/IL-1R osteoblastoma cells in which IL-1RI is constitutively overexpressed. Fig. 5 panels E–H show the localization of transfected HA-Tollip and endogenous SUMO-1 in SAOS-2/IL-1R cells. The distribution of the proteins is altogether similar to that observed in HeLa cells with a major difference. The nuclear bodies in these cells show a yellow colour indicating colocalization between Tollip and SUMO-1. We conclude that, in SAOS-2/IL-1R cells, Tollip together with SUMO-1 are translocated into the nucleus and internalized into nuclear bodies. The nuclear localization of Tollip may correlate with its interaction with Daxx, which is usually found in the PML nuclear bodies. Fig. 5 panels I–L show the merging of the fluorescence of the two proteins, Tollip and Daxx that, in SAOS-2/IL-1R cells, colocalize in nuclear bodies [20]. This confirms the localization of Tollip in defined nuclear structures, and suggests a nuclear role as well as its involvement in the nuclear cytoplasmic

![Figure 5. Cellular localization of Tollip.](image-url)
Tollip interaction with sumoylation enzymes

This work describes for the first time the involvement of Tollip in the sumoylation process. Through the two-hybrid screening of a rat cDNA library we have identified sequences coding for the described Tollip partners: Tom1, ubiquitin and Tollip itself. However, the presence of several recombinants coding for Ubc9, Daxx, ARIP3, and one clone coding for SUMO-1 came as a novelty. These interactors strongly suggest a role of Tollip in sumoylation. The remaining clones were not further analyzed. The identification of the binding site between HA-Tollip and the Flag-tagged ligases shows that the carboxyl-terminus of the C2 domain contains the ligase binding region. In the ARIP3 ligase, the binding region is just upstream the RING domain.

A direct interaction between Tollip and the E2/E3 sumoylation enzymes suggests that the protein is sumoylated. Sumoylation is not a stable reaction and a complex network of modifying and demodifying enzymes is present both in the nucleus and in the cytoplasm and controls the modification process [21]. In fact, Tollip sumoylation is detectable only in cells lysed in 1% SDS under conditions that block protease activity. It may be noticed that the co-transfection of 293T cells with the SUMO-1 and Tollip coding plasmids is sufficient to induce Tollip sumoylation suggesting that, under these conditions, the sumoylating enzymes are not limiting. The rat Tollip sequence contains 8 lysines as potential sumoylation sites, and it is possible that the sumoylated bands immunoprecipitated with Tollip are only due to SUMO-1 modification of the protein. However, different covalent modifications and, in particular, polyubiquitylation may occur in lysine residues either competing with each other for the same site or independently regulated by events that depend on the target of interest. Although sumoylation does not usually target proteins to destruction, it has been recently shown that sumoylated proteins may become targets of E3 ubiquitylation ligases for proteosomal degradation [18,22]. We cannot exclude that at least part of the sumoylated Tollip has a proteosomal destiny. The strong increase of the anti-SUMO-1 abs staining shown in figure 3C indicates that the overexpression of Tollip activates the overall cellular sumoylation of the proteins, thus suggesting a rather general role of Tollip in this process. Tollip sumoylation and its interaction with Ubc9 suggest a function of Tollip as a ligase. Conversely, the interaction of Tollip with three different members of the PIAS ligase family favours the idea of a sumoylation adaptor.

Tollip mediates IL-1RI sumoylation

Our experiments identify at least one sumoylation substrate of Tollip: the IL-1RI receptor. Here we show for the first time that this receptor is sumoylated. IL-1RI sumoylation occurs within the evolutionary conserved TIR domain, which is responsible for the activation of the IL-1 signaling cascade. Furthermore, the TIR domain is the site of ubiquitylation of IL-1RI mediated by Tollip. The equilibrium between receptor ubiquitylation and sumoylation is probably important in modulating the signaling cascade of IL-1, establishing the number of receptors present on the cell surface. Tollip may play a pivotal role in modulating the IL-1RI activity through the different modifications. Hoeller et al [23] have shown that monoubiquitylated sites do not interact with polyubiquitylated proteins. It is possible that monoubiquitylated Tollip interacts with the receptor stabilizing its sumoylation. Alternatively, un-ubiquitinated Tollip interacts with the polyubiquitylated IL-1 receptor accumulating it in the late endosomes for degradation.

Tollip has a nuclear function

In contrast with the instability of Tollip sumoylation, its expression in 293T cells seems to trigger stable modification of proteins other than Tollip, suggesting a general activation of the process following over-expression (Fig. 3C). One of the cellular proteins constitutively modified by SUMO-1 is the RanGTPase binding protein RanGAP-1, the binding partner of the RanBP2 ligase, a nucleoporine that serves as a docking site for the nuclear import of proteins [17,9]. Our results show that transfected Tollip co-immunoprecipitates with RanGAP-1, suggesting its role in RanGAP-1 sumoylation and nuclear cytoplasmic traffic. Accordingly, for the first time we show a nuclear localization of Tollip. We do not know what the nuclear function of Tollip may be but we can speculate on some hypothesis. Nuclear Tollip may be important for the sumoylation of nuclear substrates. Alternatively, Tollip could function as a carrier for nuclear localization of sumoylated proteins, as suggested by the interaction with RanGAP-1. Tollip may be involved in the translocation and nuclear localization of the cytoplasmic portion of a number of membrane receptors, among which the sumoylated cytoplasmic IL-1RI [24]. Sumoylation regulates different cellular processes, particularly transcriptional repression and activation [19]. The regulation of transcription occurs mainly through the recruitment of transcriptional co-repressors that cause downregulation. Daxx is a transcriptional co-repressor interacting with many sumoylated factors leading to SUMO-dependent repression and Daxx interacts with Tollip. Generally, Daxx is localized in the nucleoplasm and in defined nuclear structures, i.e. in the SUMO-modified PML bodies, in the nucleolus and interacts with CENP-C in the centromere, possibly exerting different functions in the different compartments. In conclusion, here we show that Daxx interacts and colocalizes with Tollip, thus suggesting the existence of a nuclear function of Tollip, and a role of Tollip in Daxx dependent transcriptional regulation.

Materials and Methods

Antibodies

Anti-HA, Ubc9, SUMO-1, Daxx and IL-1RI abs were purchased from Santa Cruz. Anti-Flag and anti-Actin abs were from Sigma-Aldrich, anti-RanGAP-1 abs were from Dr. A. Dasso of the National Institute of Child Health and Development, Bethesda.

Rat cDNA Library Construction and Yeast Two hybrid Screening

Total RNA was isolated from the brain of Sprague-Dawley rats and poly(A)+ RNA was purified by affinity chromatography on oligo(dT)-cellulose (Amersham Bioscience) [25]. Equal amounts of poly(A)+ RNA obtained from rat brain at 1, 2, 4, 8, 13 days of age were pooled and used to generate cDNA according to standard protocols based on the Gubler-Hoffman method [26]. The cDNA was purified using a Chroma Spin1000 column (Clontech) to select cDNAs 1 Kb long or more. The cDNA was cloned into the pJJ4-5 vector obtaining 1×10^6 independent colonies.

For the two hybrid screening, Tollip cDNA fused to the DNA-binding domain of LEX A was inserted into the pEG202 vector (bait) and transformed into the yeast strain W303 (MATa) together with the LacZ reporter plasmid pSH18-34. The cDNA library was used to transform the EGY48 (matα) yeast strain to generate a pre-transformed yeast library. The bait strain containing pEG202/
Tollip was crossed with an aliquot of the pre-transformed library strain and 5×10⁷ diploids were screened for interactors [27]. Positive clones were confirmed in a second round of screening in yeast and sequenced.

**Ethical Issues**

Experiments were authorized by the local bioethical Committee and performed according to the Italian and European Community legislation on the use of animals for experimental purposes.

**In vitro transcription, translation, and GST pull-down assays**

The Tollip cDNA sequence was inserted into the pGEX4T1 vector (Amersham Bioscience) in fusion with the Glutathione S-Transferase (GST) protein. The GST-Tollip fusion protein was expressed in E. coli cells and purified by binding to Glutathione-Sepharose beads. In vitro transcription of the identified interactors was carried out using the Riboprobe in vitro Transcription System (Promega) according to the manufacturer instructions. In vitro translation was carried out using the Rabbit Reticulocyte Lysate System (Promega) in presence of [35S]-methionine (Amersham Bioscience). The GST pull-down assays were carried out by incubating equal amounts of GST or GST-Tollip immobilised to Glutathione-Sepharose beads (Amersham Bioscience) with 5 µl of 35S-labelled translation product in 100 µl final volume binding buffer: 20 mM sodium phosphate pH 6, 150 mM NaCl, 10% glycerol, 1 mM PMSF, 1 mM DTT, 0.02% Nonidet P-40. The mixtures were incubated 3 h at room temperature and washed three times with binding buffer. Bound proteins were eluted with 2× SDS buffer, separated by SDS-PAGE and visualised by autoradiography.

**Cell lines and cDNA constructs**

293T and SAOS-2/IL-1RI (overexpressing IL-1RI) cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37 °C and 5% CO₂. The cDNAs coding for rat Tollip wild type and its deletion mutants were cloned into the pRK7-HA expression vector. The cDNAs coding for rat Ubc9, the cytoplasmic region of the rat IL-1RI was cloned into the pRK7-HA expression vector. The Tollip cDNA sequence was inserted into the pGEX4T1 vector (Amersham Biosciences). 40 µg protein extracts were immunoprecipitated overnight with the specific abs and separated on Protein A-Sepharose beads (Amersham Biosciences). 40 µg protein extracts were loaded on the gel to check the efficiency of the transfection.

Unless otherwise stated, the protein extracts and immunoprecipitates were analyzed in 12% SDS-PAGE. The western blots were carried out using the BioRad apparatus according to the manufacturer instructions. Staining was carried out with the ECL Western Blot Detection Reagent (Amersham Biosciences) according to the instructions.

**Immunofluorescence**

SAOS-2/IL-1RI and HeLa cells were seeded onto collagen-coated glass covers and, after 24 hr, fixed in 4% PFA for 20’ at 4 °C. Following 5’ incubation in 0.1% Triton X-20, 3%BSA the cells were stained with mouse anti-Tollip and rabbit anti-SUMO-1 abs followed by incubation with FITC conjugated anti-mouse and Cy5 conjugated anti-rabbit secondary abs. After staining, the cells were analyzed by confocal microscopy. Confocal images were acquired using a Radiance 2000 confocal laser scanning microscope (BioRad), equipped with a Nikon x60, oil immersion 1.4 N.A. objective and with krypton and red diode lasers. For FITC and Cy5 double detection, the samples were simultaneously excited with the 488-nm line of the krypton laser and with the 637-nm line of the red diode laser. The emission signals from FITC and Cy5 were separated by a dichroic mirror (DM; 560 nm) and simultaneously detected by two photomultiplier tubes. Two barrier filters (BP; 515/30 nm for FITC and LP; 660 nm for Cy5) were placed before the two photomultiplier tubes to minimize the overlap between the two signals, as previously described. Optical sections were obtained at increments of 0.3 µm in the Z-axis and were digitized with a scanning mode format of 512×512 pixels and 256 grey levels. Image processing and volume rendering (extended focus and surface-shaded) were carried out using the ImageSpace software (Molecular Dynamics; Sunnyvale, CA) running on a workstation Indigo (Silicon Graphics, Mountain View, CA.).

**Acknowledgments**

We are very grateful to Dr. Dasso, the National Institute of Child Health and Development, Betsda, for providing the anti RanGap-1 antibodies; to Dr. Marmiroli, University of Modena, for providing the SAOS-IL1R1 cell line; to Dr. Elisabetta Ciani, University of Bologna for providing the PKR7 and PKR7-HA plasmids.

**Author Contributions**

Conceived and designed the experiments: AC RD MM. Performed the experiments: AC RD CC AR SS MR SC AM SP EC. Analyzed the data: AC RD MM. Wrote the paper: MM.

**References**

1. Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, et al. (2000) Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat Cell Biol 2: 496–51.
2. Shih SC, Prag G, Francis SA, Satanso MA, Hurley JH, et al. (2003) A ubiquitin-binding motif required for intramolecular monoubiquitylation, the CUE domain. EMBO J 22: 1273–81.
3. Yamakami M, Yoshimori T, Yokosawa H (2004) Tom1 (target of Myb 1) is a novel negative regulator of interleukin-1- and tumor necrosis factor-induced signaling pathways. Biol Pharm Bull 27: 564–6.
4. Yamakami M, Yokosawa H (2004) Tom1, a VHS domain-containing protein, interacts with Tollip, ubiquitin, and clathrin J Biol Chem 279: 52865–72.
5. Zhang G, Ghosh S (2002) Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem 277: 7059–65.
6. Katoh Y, Shiba Y, Mitsuhashi H, Yanagida Y, Takatsu H, et al. (2004) Tollip and Tom1 form a complex and recruit ubiquitin-conjugated proteins onto early endosomes. J Biol Chem 279: 24433–43.
7. Katoh Y, Imakagura H, Futatsuumi M, Nakayama K (2006) Recruitment of clathrin onto endosomes by the Tom1-Tollip complex. Biochem Biophys Res Commun 341: 143–9.
8. Brissoni B, Agostini L, Kropf M, Martinon F, Swoboda V, et al. (2006) Intracellular trafficking of interleukin-1 receptor I requires Tollip. Curr Biol 16: 2265–70.
9. Pichler A, Gast A, Seeler JS, Dejean A, Melchior F (2002) The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 108: 109–20.
10. Kagey MH, Melhuish TA, Wotton D (2003) The polycomb protein Pc2 is a SUMO E3. Cell 113: 127–37.
11. Dedhar S (1989) Signal transduction via the beta 1 integrins is a required intermediate in interleukin-1 beta induction of alkaline phosphatase activity in human osteosarcoma cells. Exp Cell Res 183: 207–14.
12. Rodan SB, Wesolowski G, Chin J, Limjoco GA, Schmidt JA, et al. (1990) IL-1 binds to high affinity receptors on human osteosarcoma cells and potentiates prostaglandin E2 stimulation of cAMP production. J Immunol 145: 1231–1237.
13. Muulnen AM, Karvonen U, Poukka H, Yan W, Toppari J, et al. (1999) A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins. J Biol Chem 274: 3700–4.
14. van den Akker E, Aso N, Shih HM, Wang LC, Pironin M, et al. (2005) FLI-I functionally interacts with PIASalpha, a member of the PIAS E3 SUMO ligase family. J Biol Chem 280: 38035–46.
15. Johnson ES (2004) Protein modification by SUMO. Annu Rev Biochem 73: 355–82.
16. Hay RT (2005) SUMO: a history of modification. Mol Cell 18: 1–12.
17. Pichler A, Melchior F (2002) Ubiquitin-related modifier SUMO1 and nucleocytoplasmic transport. Traffic 3: 381–7.
18. Meulmeester E, Melchior F (2006) Cell biology: SUMO. Nature 432: 709–11.
19. Zhao J (2007) SUMOylation regulates diverse cellular processes. Cell Mol Life Sci 64: 3017–33.
20. Shih HM, Chang CC, Kuo HY, Lin DY (2007) Daxx mediates SUMO-dependent transcriptional control and subnuclear compartmentalization. Biochem Soc Trans 35: 1397–400.
21. Melchior F, Schergaut M, Pichler A (2003) SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem Sci 28: 612–8.
22. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, et al. (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10: 535–46.
23. Hoeller D, Crosetto N, Blagoev B, Raiborg C, Tikkanen R, et al. (2006) Regulation of ubiquitin-binding proteins by monoubiquitination. Nat Cell Biol 8: 163–9.
24. Lin S, Makino K, Xia W, Matin A, Wen Y, et al. (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802–808.
25. Edmonds M, Vaughan MH Jr, Nakazato H (1971) Polyadenylic acid sequences in the heterogeneous nuclear RNA and rapidly-labeled polyribosomal RNA of HeLa cells: possible evidence for a precursor relationship. Proc Natl Acad Sci U S A 6: 1336–40.
26. Gubler U, Hoffman BJ (1983) A simple and very efficient method for generating cDNA libraries. Gene 25: 263–9.
27. Kolonin MG, Zhong J, Finley RL (2000) Interaction mating methods in two-hybrid systems. Methods Enzymol 328: 26–46.
28. Di Giorno R, Riccio M, Sunti S, Galeotti C, Ambrosini DC, et al. (2002) New insights into the molecular basis of Progressive Myoclonus Epilepsy (PME1): a multiprotein complex with cystatin B. Human molecular genetics 11: 2941–2950.